Table 2.
Relationship between the BRAFV600E mutation and clinicopathological factors in PTC.
| Total, n (%) | BRAFV600E mutation, n (%) | χ 2 | P value | ||
|---|---|---|---|---|---|
| Mutation (n = 170) | Wild (n = 373) | ||||
| Gender | 2.288 | 0.130 | |||
| Female | 409 (75.3) | 121 (29.6) | 288 (70.4) | ||
| Male | 134 (24.7) | 49 (36.6) | 85 (63.4) | ||
| Age at diagnosis | 0.234 | 0.629 | |||
| <45 | 219 (40.3) | 66 (30.1) | 153 (69.9) | ||
| ≥45 | 324 (59.7) | 104 (32.1) | 220 (69.7) | ||
| Multifocality | 0.314 | 0.575 | |||
| No | 313 (57.6) | 95 (30.4) | 218 (69.6) | ||
| Yes | 230 (42.4) | 75 (32.6) | 155 (67.4) | ||
| Bilaterality | 4.703 | 0.030 | |||
| No | 418 (77.0) | 121 (28.9) | 297 (71.1) | ||
| Yes | 125 (23.0) | 49 (39.2) | 76 (60.8) | ||
| Tumor size (cm) | 31.109 | <0.001 | |||
| ≤1 | 345 (63.5) | 79 (22.9) | 266 (77.1) | ||
| >1 | 198 (36.5) | 91 (46.0) | 107 (54.0) | ||
| Extrathyroidal invasion | 23.142 | <0.001 | |||
| No | 184 (33.9) | 33 (17.9) | 151 (82.1) | ||
| Yes | 359 (66.1) | 137 (38.2) | 222 (61.8) | ||
| LNM | 7.452 | 0.006 | |||
| No | 222 (40.9) | 55 (24.8) | 167 (75.2) | ||
| Yes | 321 (59.1) | 115 (35.8) | 206 (64.2) | ||
| AJCC stage | 6.741 | 0.072 | |||
| I | 434 (79.9) | 132 (30.4) | 302 (69.6) | ||
| II | 6 (1.1) | 2 (33.3) | 4 (66.7) | ||
| III | 70 (12.9) | 19 (27.1) | 51 (72.9) | ||
| IV | 33 (6.1) | 17 (51.5) | 16 (48.5) | ||